EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

SGLT2 Inhibitors and the Risk of Urogenital Infections: A Concise Review

Luminita-Georgeta Confederat iD, Oana-Maria Dragostin, Mihaela-Iustina Condurache

Journal of Clinical Medicine · 14.03.2025 · 14 (6) · 1960

DOI: 10.3390/jcm14061960 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.03.2025. Verfasst von Luminita-Georgeta Confederat und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, "Grigore T. Popa" University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Grigore T. Popa” University of Medicine and Pharmacy Iasi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus has become a major public health problem due to aspects such as an alarming increase in prevalence, the morbidity and mortality associated with its complications and, not least, the economic burden. SGLT2 inhibitors are a relatively new but valuable class of drugs that demonstrated multifaceted effects in addition to hypoglycemic action. Moreover, these drugs demonstrated cardiovascular and renal benefits, even in individuals without diabetes, being recommended by current guidelines to patients with a history of cardiovascular disease, or at high risk for it, as well as to patients with chronic kidney disease. The prescription of this class of drugs is limited by the risk of urogenital infections, despite their multiple demonstrated benefits. Data regarding the prevalence of SGLT2 inhibitors associated with urogenital infections depend on several factors related to the study carried out and to other additional conditions that could precipitate such infections. While SGLT2 inhibitors have a well-established association with the risk of genital infections, the association with urinary tract infections remains controversial and uncertain. This review will be focused on urogenital infections associated with the administration of SGLT2 inhibitors, highlighting their prevalence, risk factors, mechanisms involved, clinical relevance and particularities of management.

Schlagwörter

Stichwörter der Autor:innen

SGLT2 inhibitorsclinical impactprevalencerisk factorsurogenital infections

Autor:innen und Institutionen

  • Department of Biomedical Sciences, "Grigore T. Popa" University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania.
  • Research Centre in the Medical-Pharmaceutical Field, Faculty of Medicine and Pharmacy, "Dunarea de Jos" University of Galati, 800008 Galati, Romania.

ORCID-Profile: Luminita-Georgeta Confederat

Förderung

  • “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Zitieren

APA

Confederat, L. G., Dragostin, O. M., & Condurache, M. I. (2025). SGLT2 Inhibitors and the Risk of Urogenital Infections: A Concise Review. Journal of Clinical Medicine, 14(6), 1960. https://doi.org/10.3390/jcm14061960

Vancouver

Confederat LG, Dragostin OM, Condurache MI. SGLT2 Inhibitors and the Risk of Urogenital Infections: A Concise Review. Journal of Clinical Medicine. 2025;14(6):1960. doi:10.3390/jcm14061960

BibTeX
@article{Confederat2025,
  author = {Confederat, Luminita-Georgeta and Dragostin, Oana-Maria and Condurache, Mihaela-Iustina},
  title = {SGLT2 Inhibitors and the Risk of Urogenital Infections: A Concise Review},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {6},
  pages = {1960},
  doi = {10.3390/jcm14061960}
}
Kostenlos starten →